Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.815 USD | -1.89% | +3.12% | -32.02% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.44M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -26M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.14
x | P/E ratio 2025 * |
-0.08
x | Employees | 12 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.68% |
Latest transcript on Cyclacel Pharmaceuticals, Inc.
1 day | -1.89% | ||
1 week | +3.12% | ||
Current month | -13.98% | ||
1 month | -22.77% | ||
3 months | -13.98% | ||
6 months | -81.15% | ||
Current year | -32.02% |
Managers | Title | Age | Since |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 97-07-31 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01-12-31 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-12-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 83 | 06-02-28 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-12-16 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 97-07-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 1.815 | -1.89% | 10 137 |
24-04-18 | 1.85 | -5.61% | 37,911 |
24-04-17 | 1.96 | +17.37% | 115,080 |
24-04-16 | 1.67 | +6.37% | 48,891 |
24-04-15 | 1.57 | -10.80% | 38,778 |
Delayed Quote Nasdaq, April 19, 2024 at 02:32 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.02% | 2.44M | |
-3.05% | 102B | |
+1.85% | 96.07B | |
-1.80% | 21.66B | |
-17.21% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.16% | 13.79B | |
+0.05% | 13.33B | |
+20.27% | 10.94B |
- Stock Market
- Equities
- CYCC Stock